Avlayah (tividenofusp alfa-eknm)
Denali Therapeutics (DNLI)
ApprovedMar 24, 2026
Marketer take
Enters Hunter syndrome, where Elaprase has long been the standard enzyme therapy, so metabolic geneticists, lysosomal disease centers and families will look for clear differentiation; it was designed to reach the brain.
- Sponsor company
- Denali Therapeutics (DNLI)
- Indication
- To treat certain individuals with Hunter syndrome (Mucopolysaccharidosis type II or MPS II)
- Therapeutic area
- Rare disease
- Event
- FDA approval
- Date
- Mar 24, 2026
- Status
- Approved
- Source
- FDA page
- Last verified
- Nov 15, 2026
Dates and status come from the linked public source as of the last verified date. Spot an error or have an update?